NEW YORK – Tempus AI this week announced that it has completed its previously announced acquisition of Ambry Genetics for $375 million in cash and $225 million in shares at closing, of which $100 million is subject to a lock-up agreement until one year after the transaction. Financing was provided by Ares Management Credit funds. Ambry will continue to operate as a wholly owned subsidiary of Tempus under its current leadership team.
Myriad Genetics announced this week that it partnered with Interlink Care Management to make its MyRisk with RiskScore hereditary cancer test available to qualifying patients in Interlink’s CancerCARE network. Patients in that network will have access to Myriad’s guideline-based MyGeneHistory online patient screening tool, and if criteria are met, they will be referred to a clinician who can order MyRisk on their behalf. Those patients will also be able to review their results with one of Myriad’s genetic counselors.
23andMe disclosed in a filing with the US Securities and Exchange Commission that the net loss for its fiscal Q3, covering the three months ending Dec. 31, was approximately $53 million, or $2.01 per share. It had previously reported a net loss of $45.5 million, or $1.73 per share, for the quarter. The Sunnyvale, California-based company also reported greater SG&A spending in the new filing. The firm spent approximately $45 million in SG&A for Q3. It had previously reported approximately $37.3 million.
DNAnexus said this week that it has expanded its partnership with life sciences cloud-computing company Veeva Systems to advance cloud-based global regulatory collaboration. One component of the partnership includes integrating Veeva RIM (regulatory information management) with DNAnexus' TRS (trusted regulatory spaces). This integration will enable Veeva RIM users to establish secure collaboration zones with international agencies to share data for regulatory review, validation, and analysis, DNAnexus said.
Dovetail Genomics said this week that it has added the HudsonAlpha Institute for Biotechnology Genome Sequencing Center as the first North American member of the Dovetail-certified service provider program. As a service provider, HudsonAlpha will provide linked-read sequencing services in the US using the Dovetail Omni-C assay. "We are thrilled to formalize their inclusion in the certified service provider program for our Omni-C chemistry and we look forward to expanding this partnership to include our additional chemistries, including LinkPrep," Dovetail CEO Matt Easterday said in a statement.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on GenomeWeb.